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Canine platelets express functional Toll-like
receptor-4: lipopolysaccharide-triggered
platelet activation is dependent on
adenosine diphosphate and thromboxane
A2 in dogs
Ronald H. L. Li1* , Nghi Nguyen1 and Fern Tablin2
Abstract
Background: Functional Toll-like receptor 4 (TLR4) has been characterized in human and murine platelets indicating that
platelets play a role in inflammation and hemostasis during sepsis. It is unclear whether canine platelets could express
functional TLR4 by responding to its ligand, lipopolysaccharide (LPS). We sought to determine if dogs express functional
TLR4 and if LPS-induced platelet activation requires co-stimulation with ADP or thromboxane A2 (TxA2). Canine platelets
were unstimulated (resting) or activated with thrombin or ADP prior to flow cytometric or microscopic analyses for TLR4
expression. We treated resting or ADP-primed platelets with LPS in the absence or presence of acetylsalicylic acid (ASA)
and inhibited TLR4 with function blocking antibody or LPS from Rhodobacter sphaeroides (LPS-RS).
Results: We discovered that dog platelets have variable TLR4 expression, which was upregulated following thrombin or
ADP activation. LPS augmented P-selectin expression and thromboxane B2 secretion in ADP-primed platelets via TLR4.
Inhibition of cyclooxygenase by ASA attenuated LPS-mediated P-selectin expression demonstrating that TLR4 signaling in
platelets is partially dependent on TxA2 pathway.
Conclusion: Expression of functional TLR4 on canine platelets may contribute to hypercoagulability in clinical septic dogs.
Cyclooxygenase and TxA2 pathways in TLR4-mediated platelet activation may present novel therapeutic targets in dogs
with sepsis.
Keywords: Sepsis, Thrombosis, Platelet-priming, Inflammation, Aspirin, Pattern recognition receptor
Background
Despite recent advances in veterinary medicine, mor-
tality remains high in dogs with sepsis secondary to
Gram negative bacterial infections [1–3]. One of the
major components of the outer membrane of Gram
negative bacteria is the endotoxin, lipopolysaccharide
(LPS), whose receptor, Toll-like receptor 4 (TLR4), is
present on the surface of a wide variety of immune
cells such as dendritic cells, epithelial cells, poly-
morphonuclear cells and macrophages. Formation of
the TLR4 receptor complex in response to LPS initi-
ates signalling pathways leading to proinflammatory
cytokine production and inflammatory response. In
addition to being the primary effector cell in
hemostasis, there is growing evidence demonstrating
that platelets function as innate immune cells [4].
Bacteria like E.coli and Streptococcus directly interact
with platelets leading to platelet activation and
aggregation [5]. Murine and human platelets also ex-
press several Toll-like receptors (TLRs), suggesting
that platelets can act as sentinel cells in detecting
pathogen-associated molecular patterns (PAMPs) like
LPS.
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Thrombocytopenia, a common finding in septic dogs,
is associated with mortality, though the exact mechan-
ism of this hematologic abnormality is poorly under-
stood [6–8]. Proposed mechanisms of sepsis-associated
thrombocytopenia include decreased thrombopoiesis
and increased platelet consumption and sequestration.
Systemic platelet activation, which precedes platelet
accumulation in organs and microvasculature in human
septic patients, suggests that platelets may be the key
effector for systemic coagulation during bacterial infec-
tion [9]. Systemic hypercoagulability could progress to
disseminated intravascular coagulation, further impeding
blood flow to tissues causing organ dysfunction. Andone-
gui et al. showed that platelet TLR4 is an important regu-
lator of endotoxin-mediated thrombocytopenia in mice
[10]. In another in vivo sepsis model, transfusion of TLR4
deficient platelets in platelet-depleted mice attenuated
microvascular thrombosis [11]. These studies suggest that
platelet TLR4 also may play a role in facilitating platelet
activation in sepsis leading to microvascular thrombosis,
and organ dysfunction in septic dogs. [10, 11] This, how-
ever, has never been demonstrated in this species. In one
of the few canine studies, Yilmaz et al., demonstrated in-
creased platelet aggregation in a lethal endotoxin shock
model [8]. Another study, however, found that circulating
platelets in dogs with septic peritonitis have decreased ag-
gregation in response to multiple agonists [12].
The mechanism of platelet activation in sepsis has
been extensively studied in mice and humans with con-
flicting results. While some investigators found that LPS
stimulates human platelets to undergo activation and ag-
gregation, others found that LPS does not directly stimu-
late platelets or that LPS-triggered activation requires
synergistic stimulation by platelet agonists like ADP, col-
lagen and thromboxane A2 (TxA2) [5, 13–16]. Because
platelet activation mediated by TLR4 may account for
the interplay between sepsis and thrombosis in dogs, a
better understanding of platelet TLR4 expression and
platelet response to LPS, is needed. We, therefore, aimed
to examine platelet membrane TLR4 expression and de-
termine if this expression is altered by the platelet ago-
nists, ADP and thrombin. We also aimed to determine if
LPS could activate platelets via TLR4. Specially, we
sought to determine if LPS, in the absence or presence
of ADP or TxA2, could stimulate platelet alpha-granule
secretion. Lastly, we sought to determine if inhibition of
platelet TLR4 could attenuate platelet response to LPS
in the absence or presence of platelet priming by ADP.
Results
Out of the 30 dogs studied, 14 dogs were female and 16
dogs were male. Age ranged from 0.33 to 13 years of age
(mean 4.92). Of the 30 dogs, 19 were mixed breed dogs;
11 were purebreeds including 2 Labrador Retreivers, 5
Golden Retreivers, 1 Cataoula Hog Dog, 1 Weimaraner,1
Akbash Coban and 1 Bouvier des Flandres.
Canine platelets express surface TLR4 and its expression
is upregulated by thrombin and ADP
Resting platelets had a low surface expression of TLR4
(9.50%; IQR = 0.70–16.88) and the expression was highly
variable among subjects with a coefficient of variation
(CV) of 135.54%. Thrombin or 10 μM ADP significantly
increased the number of TLR4-positive platelets relative
to resting platelets (20.80%, IQR = 5.39–43.43, p =
0.0078; 12.12%, IQR = 1.31–45, p = 0.016, respectively)
(Fig. 1a to d). CVs of TLR4 expression in thrombin- and
ADP-stimulated platelets were 85 and 97.62%, respect-
ively. ADP increased TLR4 expression in a dose-
dependent manner (p = 0.047) (Fig. 1d). Compared to
ADP-stimulated platelets, thrombin stimulation resulted
in higher TLR4 MFI fold change (0.065 ± 0.064 vs.
0.14 ± 0.12), but this difference did not reach statistical
significance (p = 0.078). Flow cytometry findings were
confirmed by directly visualizing surface TLR4 expres-
sion using confocal and STED immunofluorescence mi-
croscopy. The platelet membrane was identified by
detecting the highly expressed platelet integrin subunit,
β3 (Fig. 2). As expected, resting platelets have minimal
exteriorization of P-selectin and TLR4 was either spar-
cely expressed or expressed in clusters on the cell mem-
brane of unpermeabilized platelets (Fig. 2a, arrow).
Following ADP or thrombin-induced activation, surface
expression of TLR4 and P-selectin was upregulated on
the platelet membrane. Compared to the clustered con-
formation seen on resting platelets, TLR4 was distrib-
uted evenly on the membrane surface (Fig. 2b, c). In
addition, co-localization of TLR4 and P-selectin on the
membrane surface was detected on either ADP or
thrombin-stimulated platelets (Fig. 2b, c). We then
determined the location of intracellular TLR4 by perme-
abilizing fixed resting platelets prior to immunostaining.
We found that TLR4 (Fig. 2d, Merge, arrows) was con-
centrated within the platelet alpha-granules as outlined
by P-selectin (Fig. 2d, P-selectin, asterisks).
LPS has a limited ability to stimulate alpha-granule
secretion in canine platelets
To determine if LPS could activate canine platelets, we
measured surface P-selectin expression, using flow
cytometry, as a marker of alpha-granule secretion fol-
lowing treatment with 0, 1, 5 or 10 μg/ml LPS. P-selectin
expression on resting platelets was highly variable
among dogs (Range 2 to 34%, CV = 73.59%) despite a
standardized protocol (Fig. 3a,b). Although we could not
find a dose-dependent effect of LPS on platelet P-
selection expression (% P-selectin-positive platelets, p =
0.11; P-selectin MFI fold change, p = 0.38), 5 μg/ml LPS
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significantly elevated the number of P-selectin-positive
platelets compared to resting platelets (26.23% ± 17.24
vs. 17.85% ± 10.53, p = 0.041) (Fig. 4a). This elevation
was similar to surface P-selectin expression in thrombin-
stimulated platelets (36.14% ± 20.85, p = 0.066). Treat-
ment with either 1 or 10 μg/ml LPS did not significantly
increase the number of P-selectin-positive platelets com-
pared to resting platelets (16.82% ± 12.65, p = 0.74;
21.62% ± 15.4, p = 0.32, respectively) (Fig. 4a). No signifi-
cant differences between P-selectin MFI fold change in
platelets treated with 1, 5 or 10 μg/ml LPS (0.041 ± 0.11,
0.044 ± 0.047, 0.0064 ± 0.081, respectively, p > 0.05) were
found. Compared to thrombin as an agonist (0.5873 ±
0.38), LPS stimulation resulted in significantly lower P-
selectin MFI fold change (1 μg/ml, p = 0.0057; 5 μg/ml,
p = 0.0045; 10 μg/ml, p = 0.0018) (Fig. 4c). Similarly,
stimulation of platelets with all concentrations of LPS
did not result in significant changes in the number of P-
selectin-positive PDMV (p = 0.4833) nor MFI fold
change (p = 0.22).
Platelet priming by ADP potentiates LPS-mediated alpha-
granule secretion
To determine if ADP could augment platelet response to
LPS, we first primed platelets with 10 μM ADP, followed
by 1, 5 or 10 μg/ml LPS. Compared to platelets treated
with 5 μg/ml LPS alone, ADP priming prior to treatment
with LPS of the same concentration resulted in signifi-
cant elevation in P-selectin (20.51% ± 17.44 vs. 33.20% ±
19.83, p = 0.0032; MFI fold change 0.044 ± 0.047 vs.
0.18 ± 0.13, p = 0.0092) (Fig. 4b, c). ADP-priming prior
to LPS stimulation also led to significant increase in P-
selectin expression compared to platelets activated with
ADP alone (MFI fold change: 0.18 ± 0.13 vs. 0.13 ± 0.14,
Fig. 1 Platelet activation upregulates surface TLR4 expression. Platelet surface TLR4 expression was measured on isolated platelets from 10 dogs
using flow cytometry. a,c Representative histograms of resting (unstimulated) platelets (grey) and activated platelets (clear) indicating increase in
surface TLR4 expression following thrombin (a) and ADP (c) activation. b Thrombin stimulation led to significant increase in percentage (%) of
TLR4-positive platelets compared to resting platelets. d Platelets stimulated with 10 μM ADP had significantly higher percentage of TLR-positive
platelets. First and third quartiles were represented by the lower and upper boundaries, respectively. + and the line within the box represents the
mean and median, respectively. Whiskers represent the range of data. * p < 0.05
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p = 0.038) (Fig. 4c). When ADP-primed platelets were
treated with 10 μg/ml LPS, P-selectin MFI fold was sig-
nificantly higher compared to unprimed platelets treated
with the same concentration of LPS (MFI fold change
0.11 ± 0.070 vs. 0.0064 ± 0.08, p = 0.00020) but this eleva-
tion did not differ from that in ADP-treated platelets
(p = 0.059) (Fig. 4c). ADP-priming followed by LPS
stimulation significantly increased the number of P-
selectin-positive platelets relative to ADP-activated
platelets (35.01% ± 20.48 vs 29.88% ± 19.70, p = 0.035)
and unprimed platelets treated with 1 μg/ml LPS
(35.01% ± 20.48 vs 16.82% ± 12.65, p = 0.013) (Fig. 4b).
TLR4 expression (MFI fold change) in resting platelets
did not correlate with LPS-induced P-selectin expression
(MFI fold change) in unprimed platelets (r = 0.25, r2 =
0.065, p = 0.51). Following ADP priming, however, TLR4
Fig. 2 Representative confocal and super resolution immunofluorescence microscopy demonstrating TLR4 expression on a resting, b ADP-, c thrombin-
activated and d permabilized resting canine platelets. a-c Following activation, platelets were fixed and stained for TLR4 (red), P-selectin (green) and the
integrin β3 (blue). a In the absence of platelet agonists, resting platelets as outlined by the abundant integrin β3 show limited to no expression of P-
selectin on the membrane surface. Note the aggregregated appearance of exteriorized TLR4 (arrow) b,c In ADP- and thrombin-activated platelets, TLR4
expression is upregulated and is evently distributed across the membrane surface. Note the formation of pseudopodia and colocalization of TLR4 and P-
selectin (arrowheads) on activated platelets c Extensive platelet aggregation can be seen in thrombin-activated platelets. Scale bar = 5 μm. Original
magnification 100x d Resting platelets were fixed, permabilized and stained for TLR4 (red) and P-selectin (green). A single z-plane is shown here to
demonstrate the presence of alpha-granules within a platelet (asterisk). Intracellular TLR4 can be seen within the alpha-granules (arrows). Scale bar = 4 μm.
Experiment was replicated twice from platelets isolated from 2 dogs
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expression was positively and moderately correlated with
LPS-mediated P-selectin expression (r = 0.70, r2 = 0.49,
p = 0.036).
ADP priming augments LPS-induced TxA2 synthesis
To examine if LPS augments platelet TxA2 synthesis in
the presence or absence of ADP, we measured TxB2 con-
centrations in platelet supernatant using ELISA. Using
ASA-treated platelets as negative controls, we found that
LPS did not significantly elevate TxB2 secretion relative
to ASA-treated platelets (1460 pg/ml, IQR: 695.4–3048
vs. 952 pg/ml, IQR: 495.3–2062, p = 0.06). TxB2 concen-
tration in LPS-treated platelets also was similar to that
in resting platelets (1460 pg/ml, IQR: 695.4–3048 vs.
1839 pg/ml, IQR: 887.1–2788, p > 0.99). Following prim-
ing with ADP, LPS resulted in significant elevation in
TxB2 secretion (3988 pg/ml IQR: 1042–6459) compared
to resting platelets (p = 0.0020) and AA-reated platelets
(p = 0.005). ADP-priming prior to LPS treatment also
significantly increased TxB2 secretion compared to
stimulation with LPS (p = 0.0039) or ADP (1637 pg/ml,
IQR: 921.3–5530, p = 0.0039) alone (Fig. 5a).
LPS-mediated alpha granule secretion requires TxA2
To determine whether TxA2 was required for LPS-
mediated alpha granule secretion, we first treated platelets
with ASA prior to LPS stimulation in the absence or pres-
ence of ADP. We found that ASA did not significantly
affect the number of P-selectin-positive platelets in resting
(ASA: 8.06%, IQR:6.38–16.12 vs. Resting: 7.87%, IQR:
6.94–17.54, p = 0.84) (Fig. 5b) or ADP-stimulated platelets
(ASA +ADP: 23.85%, IQR:16.53–36.18 vs. ADP: 32.25%,
IQR:18.00–44.50, p = 0.10) . ASA also did not affect P-
selectin MFI fold change in platelets activated with LPS
(ASA + LPS: 0.014, IQR: − 0.043 – 0.045 vs. LPS:0.015,
IQR: − 0.042 – 0.14, p = 0.37) or ADP (ASA +ADP: 0.15,
IQR: 0.083–0.25 vs. ADP: 0.13, IQR: 0.097–0.29, p = 0.74)
(Fig. 5c).
In unprimed platelets treated with LPS, number of P-
selectin positive platelets was significantly lower in those
with ASA treatment compared to those without (10.54%,
Fig. 3 Variability of P-selectin expression on unstimulated/resting platelets. Representative histograms and scatter plots of flow cytometric analysis
of unstimulated platelets isolated in 2 dogs on the same day. Platelets were identified by their light scatter properties and binding of CD61. Histogram
demonstrates the number of activated platelets shown as P-selectin positive. a Resting platelets with mimimal P-selectin positive platelets and characteristic
light scatter profile of canine platelets. b Unstimulated platelets collected from a different dog showed increased P-selectin-positive platelets with side-scatter
property indicative of increased degranulation (arrow)
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IQR: 4.72–19.33 vs 6.97%, IQR: 4.15–14.45, p = 0.031).
Inhibition of TxA2 synthesis by ASA also significantly at-
tenuated the number of P-selectin positive platelets in
ADP-primed platelets treated with LPS (16.35%, IQR:
11.03–31.63 vs. 28.15%, IQR: 15.33–31.68, p = 0.05) but
not in P-selectin MFI fold change (0.13 ± 0.086 vs.
0.16 ± 0.071, p = 0.83) (Fig. 5b,c).
LPS-mediated alpha-granule secretion is dependent on
TLR4
To investigate if LPS-mediated alpha granule secretion
in platelets is dependent on TLR4, platelets were pre-
treated with TLR4 function blocking antibodies. We
confirmed that TLR4 inhibition using a function block-
ing antibody did not interfere with detection of P-
selectin expression in either resting or ADP-activated
platelets (Fig. 6a, b). However, TLR4 inhibition signifi-
cantly attenuated P-selectin expression in LPS-treated
platelets. P-selectin MFI fold change in LPS-treated
platelets was significantly decreased compared to those
without TLR4 inhibition (− 0.032 ± 0.023 vs. 0.0017 ±
0.031, p = 0.021) or those treated with the isotype con-
trol (− 0.032 ± 0.023 vs 0.076 ± 0.031, p = 0.004) (Fig. 6a).
TLR4 inhibition, however, did not significantly alter the
percentage of P-selectin positive platelets in LPS-
stimulated platelets (5.75 ± 1.32 vs 6.25 ± 3.93, p = 0.66).
In ADP-primed platelets, TLR4 inhibition significantly
decreased LPS-mediated P-selectin MFI fold change
(0.061 ± 0.066 vs. 0.14 ± 0.11, p = 0.0127) but not the iso-
type control (0.12 ± 0.11, p = 0.58). (Fig. 6b).
Inhibition of TLR4 with LPS-RS, a TLR4 antagonist,
had no attenuating effect on LPS-mediated P-selectin
expression in unprimed platelets. However, in the pres-
ence of ADP, LPS-RS significantly lowered LPS-
mediated P-selectin expression. Compared to vehicle
Fig. 4 ADP-priming augments LPS-mediated alpha-granule secretion
in canine platelets. Platelet alpha-granule secretion was assessed by
surface P-selectin (CD62P) measured as percent (%) positive or mean
fluorescence intensity (MFI) fold change on isolated platelets from
10 dogs using flow cytometry. Thrombin-stimulated platelets served
as positive control. a Platelets were treated with 0, 1, 5, or 10 μg/ml
LPS. Only platelets treated with 5 μg/mL LPS had significant increase
in CD62P+ platelets compared to unstimulated platelets. b,c Platelets
were primed with 10 μM ADP prior to stimulation with 0, 1, 5 or 10 μg/
ml LPS. LPS stimulation with 1 μg/mL LPS in ADP-primed platelets
significantly elevated the percentage of CD62P+ platelets b but did
not increase MFI fold change c compared to ADP-primed platelets
without LPS. LPS at 5 μg/mL significantly increase CD62P MFI fold
change in ADP-primed platelets relative to those without LPS. ADP
priming increased platelet response to LPS at 1 (b), 5 μg/mL (b,c) and
10 μg/mL (c). First and third quartiles were represented by the lower
and upper boundaries, respectively. + and the line within the box
represents the mean and median, respectively. Whiskers represent the
range of data. * p < 0.05, # All treatments were significantly different
(p < 0.05) from positive control
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control, TLR4 inhibition by LPS-RS significantly de-
creased the percentage of P-selectin positive platelets
(19.71% ± 10.86 vs 10.19% ± 4.51, p = 0.0003) and MFI fold
change (0.20 ± 0.17 vs 0.099 ± 0.13, p = 0.0049). (Fig. 6c).
Discussion
To the authors’ knowledge, this is the first study docu-
menting the expression of functional TLR4 in canine
platelets. The present study indicates that platelet re-
sponse to E.coli LPS via TLR4 is amplified by the ago-
nists ADP and TxA2 in dogs.
The expression of functional TLR4 on canine platelets
highlights a highly conserved mechanism of pathogen
recognition utilized by many other cell types in mam-
mals [17]. But unlike other immune cells, thrombin and
ADP, which are platelet agonists that stimulate platelets
in extending platelet plug formation, upregulate the sur-
face expression of platelet TLR4 [18]. Here, we found
that TLR4 resides within the cytoplasm and alpha gran-
ules in unstimulated platelets, similar to the findings in
human platelets. The upregulation of surface TLR4 in
thrombin-activated human platelets is secondary to the
activation of calpain with subsequent cleavage of
myosin-9 resulting in TLR4 trafficking from the alpha-
granules to the platelet plasma membrane [19]. The co-
expression of TLR4 and P-selectin on the surface of
activated canine platelets suggests that TLR4 trafficking
to the platelet surface also could be mediated by alpha-
granule secretion. This unique mechanism of TLR4 up-
regulation in platelets highlights the interplay between
hemostasis and innate immunity.
Our results indicate a highly variable expression of
surface TLR4 among dogs which is augmented once
Fig. 5 LPS amplifies ADP-mediated thromboxane B2 (TxB2) secretion
and inhibition of platelet cyclooxygenase 1 attenuates LPS-mediated
alpha-granule secretion. a Platelet TxB2 concentration was measured
by ELSIA from platelet supernatant in 10 dogs. In the presence or
absence of ADP, platelets were treated with 5 μg/ml LPS. Thrombin-
stimulated and acetyl salicylic acid (ASA)-treated platelets served as
positive and negative controls, respectively. LPS-treated platelets did
not augment TxB2 production compared to unstimulated platelets
and ADP-treated platelets. ADP priming in LPS-treated platelets led
to more TxB2 than ADP-treated platelets, LPS-treated platelets and
unstimulated platelets. b,c Isolated platelets from 10 dogs were
pretreated with 100 μM acetylsalicyclic acid (ASA) prior to treatment
with 5 μg/ml LPS with or without ADP. Platelet alpha-granule
secretion was assessed by P-selectin (CD62P) measured as percent
(%) positive b or mean fluorescence intensity (MFI) fold change c
using flow cytometry. ASA significantly decreased the % P-selectin
positive platelets a but not P-selectin MFI fold change b in LPS-
treated platelets in the absence or presence of ADP-priming. First
and third quartiles were represented by the lower and upper
boundaries, respectively, and the line within the box represents the
median. + represents the mean. Whiskers represent the range of
date. * p < 0.05, # Significance between all treatments
and controls (p<0.05)
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platelets were activated by thrombin or ADP. The sig-
nificant correlation between TLR4 expression and the
degree of LPS-mediated alpha-granule release in the
presence of ADP suggests that the upregulation of TLR4
augments platelets’ sensitivity to LPS. We further con-
firmed this finding by inhibiting TLR4 in ADP-primed
platelets. While TLR4 inhibition did not interfere with
ADP-induced activation, it abolished the stimulatory ef-
fects of LPS indicating that ADP potentiates LPS-
mediated platelet activation by upregulating surface
TLR4 expression. Dogs with naturally occurring sepsis
are found to be in a hypercoagulable state with elevated
thrombin generation and overconsumption of endogen-
ous anticoagulants like antithrombin III [20]. It is un-
known at this stage if elevated levels of thrombin in
sepsis could trigger upregulation of surface TLR4 ex-
pression in canine platelets and, thereby, increases plate-
let response to endotoxins. In people, platelet TLR4
expression is elevated during sepsis and this upregula-
tion is associated with the severity of sepsis-induced
thrombocytopenia [21]. The prognostic and diagnostic
significance of platelet TLR4 expression in dogs requires
further investigations.
We demonstrated that E.coli LPS, to a limited extent,
activates canine platelets to undergo alpha-granule se-
cretion required for normal thrombus formation. P-
selectin, a marker of alpha-granule secretion, is an inte-
gral protein of the alpha granule membrane. In accord-
ance with previous studies, we were unable to detect
significant elevation in P-selectin expression, and TxA2
generation elicited by LPS [16]. Despite finding a signifi-
cant increase in the numbers of platelets expressing P-
selectin, the lack of MFI fold change suggests that LPS
had minimal effect on augmenting P-selectin density, a
marker of substantial alpha-granule secretion. Another
explanation is the variable P-selectin expression on un-
stimulated platelets potentially due to stress from hand-
ling, excitement or in vitro platelet activation from PRP
generation (Fig. 3) [22]. This likely could decrease plate-
let sensitivity to LPS. Dogs that were easily excitable,
Fig. 6 LPS-mediated alpha-granule secretion is dependent on platelet TLR4. Platelet P-selectin (CD62P) measured as percent (%) positive platelets
or mean fluorescence intensity (MFI) fold change on isolated platelets (1 × 107/ml) from 10 dogs using flow cytometry. a, b Platelets were treated
with either 50 μg/ml TLR4 function blocking antibody or 50 μg/ml IgG2a before LPS stimulation (5 μg/ml) in absence or presence of ADP. TLR4
inhibition in LPS-treated had minimal effect on attenuating the numbers of P-selectin positive platelets (a) but significantly decreased P-selectin
MFI fold change b in the presence or absence of ADP priming. Pretreatment of platelets with LPS-RS before LPS stimulation significantly decreased
number of P-selectin postive platelets and MFI fold change only in ADP-primed platelets. First and third quartiles were represented by the lower and
upper boundaries, respectively, and the line within the box represents the median. Whiskers represent the range of data. + represents the mean * p <
0.05, #Significance between all treatments and isotype controls (p<0.05)
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stressed and difficult to restrain for blood draws were
later on excluded from the TLR4 blocking experiments, as
evidenced by the lower mean resting P-selectin expression
(Fig. 5a, c).
Once platelets are primed with ADP, treatment of plate-
lets with LPS potentiates alpha-granule secretion and
TxA2 generation, suggesting that LPS synergizes with
ADP in amplifying platelet response to LPS. This observa-
tion might be due to several underlying mechanisms. First,
surface P-selectin on human platelets has been shown to
enhance E.coli LPS binding to platelet TLR4 by forming
TLR4/CD62P receptor complex [23]. Secondly, besides
upregulating surface TLR4 on platelets, ADP, which binds
to the G-protein coupled receptors, P2Y1 and P2Y12, trig-
gers signaling events critical for robust platelet activation
to occur. For example, in murine and human platelets,
P2Y1, which couples with Gq, activates phospholipase C
(PLC) and, subsequently, 1,4,5-triphosphate (IP3) and di-
acylglycerol, to increase calcium mobilization and cyto-
solic calcium concentration, an event required to trigger
numerous cellular events including integrin activation.
Calcium mobilization via PLCγ2 also is required for TLR4
signalling in immune cells like macrophages and dendritic
cells [24]. Whether calcium flux orchestrated by ADP-
mediated signaling amplifies TLR4 downstream signaling
in canine platelets requires further investigation. In
addition to alpha-granule secretion, we also found that
LPS and ADP synergistically increase production of TxA2,
an eicosanoid converted from arachidonic acid within the
cell membrane by the enzyme, cyclooxygenase-1. This
suggests that TLR4 and ADP receptor signaling share a
similar downstream pathway that results in TxA2 gener-
ation. Nocella et al. proposed that activation of TLR4 and
ADP receptors results in amplification of the AKT-
Fig. 7 Schematic diagram of LPS-mediated platelet activation and TLR4 expression in canine platelets. ADP activation via P2Y1 or P2Y12 receptor
upregulates surface TLR4 expression. TLR4 trafficking to cell membrane from granules may be mediated by alpha-granule secretion. LPS binding
protein (LBP) presents LPS to CD14 forming a heterodimeric complex with TLR4 and myeloid differentiation protein 2 (MD-2). Downstream signaling
pathway of TLR4 leads to α-granule secretion, which is amplified by ADP and thromboxane A2 (TxA2). Activation of G-protein coupled receptors, P2Y1/
P2Y12 and thromboxane receptor (TP), leads to phospholipase C (PLC) activation and, subsequently, 1,4,5-triphosphate (IP3) and diacylglycerol (DAG)
for intracellular calcium release and alpha-granule secretion. LPS acts synergistically with ADP to increase generation of TxA2, serving a positive
feedback mediator. TLR4 and ADP signaling activates cyclooxygenase-1 (COX-1), which converts arachidonic acid (AA) to TxA2, likely by the Akt/p38
MAPK pathway
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p38MAP kinase axis leading to phospholipase A2 phos-
phorylation and subsequent generation of TxA2 in human
platelets [16]. Further studies are needed to characterize the
non-genomic pathway of TLR4 in dog platelets (Fig. 7).
By directly inhibiting the enzyme, cyclo-oxygenase
(COX-1) with ASA, we showed that platelet activation
mediated by TLR4 and ADP signaling is partially
dependent on TxA2. Given its short half-life (~ 30 s), TxA2
acts as an autocrine or paracrine to nearby platelets ampli-
flying platelet activation via platelet TxA2 receptors. As
expected, ASA did not completely attenuate LPS-
mediated alpha granule secretion and, in some dogs, had
no effect on P-selectin expression. This may be due to the
variable thromboxane responsiveness found in some dogs,
in which inhibition of TxA2 production may not nega-
tively impact LPS-mediated platelet activation [25]. This
also may be due to the presence of other mediators likely
involved in the positive feedback mechanism of TLR4
signaling. Antiplatelet therapy is the cornerstone of
antithrombotic therapy in dogs. In addition to their anti-
thrombotic properties, antiplatelet drugs have been shown
to modulate inflammation in people and dogs by reducing
acute phase response and proinflammatory biomarkers
like C-reactive protein [26]. Since TxA2 serves as a positive
feedback in amplifying LPS-mediated platelet activation,
antiplatelet therapy may have potential benefits in clinical
septic dogs [26]. In observational studies, prehospital
administration of ASA has been shown to be associ-
ated with reduced mortality and lower prevalence of
acute respiratory distress syndrome in critically ill
humans with sepsis [27, 28]. Prospective clinical trials
are needed to identify the clinical benefits of ASA
therapy in at-risk dogs.
The present study has several limitations. First, the con-
centration of LPS that consistently activated canine plate-
lets in the absence or presence of ADP was 5 μg/ml, a
higher concentration than expected in systemic circulation
during sepsis. A plausible explanation for the need of this
concentration is the low levels of plasma proteins in our
washed platelet system. The binding of LPS to TLR4 is
complex and requires 3 other extracellular proteins in-
cluding LPS binding protein (LBP), CD14, and myeloid
differentiation protein 2 (MD-2). LBP, a soluble acute-
phase protein, binds to LPS and presents it to CD14 on
platelets to form a heterodimeric complex with TLR4 and
its accessory protein, MD2 (Fig. 6). Whether human plate-
lets express CD14 is controversial [13, 29, 30]. Damien et
al. found that the response to LPS in washed platelets is
dependent on soluble CD14 suggesting that platelets may
obtain CD14 from systemic circulation [30]. We supple-
mented canine platelets with a small concentration of ca-
nine serum in order to enhance platelet response to LPS.
However, we did not investigate if canine platelets express
the necessary TLR4 signaling complex including surface
CD14 expression. Since LPS-RS antagonizes LPS by dir-
ectly competing with LPS for the binding site on MD-2,
our data suggests that dog platelets may express MD-2 on
the cell surface. Further studies using platelet rich plasma
to determine if concentrations of LPS found in septic dogs
could activate platelets is needed. Another plausible
explanation is that canine platelets may have variable
responses to LPS from different strains of E. coli as the
affinity for TLR4 on mouse platelets is dependent on the
LPS serotypes [23]. Finally, we did not investigate the ef-
fects of LPS on other markers of platelet activation such
as fibrinogen binding, dense granule secretion and CD40L
expression, which have all been shown to increase by LPS
stimulation in human and murine platelets [13, 23].
Conclusion
Our study demonstrated that canine platelets express
functional TLR4, which can be upregulated by thrombin
or ADP. Although E coli LPS is a limited stimulus for
platelet activation, in the presence of ADP or TxA2, LPS
is a potential platelet activator in dogs. The findings of
this study provide novel insights into the mechanisms of
thrombosis and potential therapeutic targets in septic
dogs.
Methods
Animals
The study protocol was approved by the Institutional
Animal Care and Use Committee at the University of
California, Davis. Thirty clinically healthy staff- or
student-owned dogs greater than 5 kg were used in this
study and 8 dogs were enrolled for each experiment. Dogs
were deemed to be clinically healthy by physical examin-
ation performed by the corresponding author and a
complete blood count using an automated hematology
analyzer (Coulter ACT diff, Beckman-Coulter Inc., Miami,
FL) and blood smear evaluation. Dogs were not enrolled
in the study if they were vaccinated 30 days prior to
enrollment, on any concurrent medications, or had any
abnormalities on hematological examination. Eight dogs
were enrolled.
Generation of gel-filtered platelets
Whole blood (4 to 6 ml) was drawn from either the
jugular or cephalic vein using a 22 gauge needle con-
nected to a 6 ml syringe before transferring into 3.2%
sodium citrate tubes. Blood tubes were gently inverted
2 to 3 times and carefully inspected for clots. Citrated
blood was transferred to polypropylene tubes and
platelet rich plasma was generated by centrifugation
(300 x g, 5 min, no brakes) at room temperature.
Platelets were separated from plasma by gel-filtration
over a Sephrose 2B column at 37 °C and eluted with
filtered Tyrodes-HEPES buffer (pH 7.4, 5 mM dextrose,
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0.5% canine serum, without divalent cations) [31]. Gel-
filtered platelets were observed to determine if they exhib-
ited the “swirling” characteristic found in truly discoid
resting platelets [31, 32]. Isolated platelets that failed to
display swirling movements were not included in the
study. Platelet count was obtained using an automated
analyzer (Coulter ACT diff, Beckman-Coulter Inc., Miami,
FL) and confirmed by bloodsmear evaluation. All experi-
ments were carried out in a sterile manner.
Detection of platelet TLR4 and P-selectin surface
expression by flow cytometry
Platelet count was adjusted to a concentration of 1 ×
107 cells/ml with Tyrodes-HEPES (pH 7.4, 5 mM dex-
trose, 0.5% canine serum, without divalent cations)
and platelets were either unstimulated (resting) or
stimulated with 0.1 unit/ml bovine-derived alpha-
thrombin (Haematologic Technologies, Inc., Essex
Junction, VT) or ADP (1 μM or 10 μM) for 15 min at
37 °C [33]. Surface TLR4 expression was assessed
using a biotinylated mouse anti-human monoclonal
antibody to TLR4 (1:400, Clone: HTA 125, BioRad
Laboratoires, Herculues, CA), known to cross react
with canine TLR4 [34]. Following 45 min of incuba-
tion at 37 °C, platelets were incubated with streptavi-
din conjugated to phycoerythrin cy7 (1:200,
Invitrogen, Carlsbad, CA) for an additional 45 min at
37 °C. For the detection of P-selectin (CD62p), plate-
lets were either resting or first primed with 10 μM
ADP (15 min, 37 °C) prior to treatment with 1, 5, or
10 μg/ml LPS from Escherichia coli 0111:B4 (EMD
Millipore, Temecula, CA) for 30 min at 37 °C. Un-
stimulated and thrombin-activated (0.1 U/ml) platelets
served as negative and positive controls, respectively.
Following activation, platelets were incubated with
fluorescein isothiocyanate-conjugated rat anti-mouse
monoclonal antibody to P-selectin (CD62p) (1:200,
Clone:RB40.34, BD Biosciences, San Diego, CA) for
45 min at 37 °C. Platelets were identified by forward and
side scatter properties as well as the platelet integrin, β3a
(CD61), using a mouse anti-human monoclonal antibody
conjugated to allophycocyanin (1:1000, Clone:VI-PL2,
eBioscience, San Deigo, CA) (45min, 37 °C). Cells were
fixed in 0.1% paraformaldehyde and analyzed using a 5-
color flow cytometer (Beckman-Coulter FC500, Beckman-
Coulter Inc., Miami, FL) within 4 h. Gating boundaries
were established by fluorescence-minus-one controls. Anti-
mouse compensation beads (BD Biosciences, San Diego,
CA) conjugated to matched experimental fluorochromes
were used for compensation and compensation matrices
were calculated using commercially available software
(FlowJo, Tree Str Inc., Ashland, OR). TLR4 and P-selectin
expression was measured as perecent positive events or fold
change in mean fluorescence intensity (MFI) between
activated platelets and resting platelets using the following
formula:
MFI fold change ¼ Log10 MFIActivated
  Log10 MFIResting
 
The platelet and platelet-derived microvesicle (PDMV)
gates were determined as previously described using
0.5 μm and 3 μm calibration beads [35, 36]. In brief,
PDMV were quantified based on either the number of
CD62P-positive events or MFI fold change in CD62P.
Flow cytometry data were analyzed using commercially
available software (FlowJo, Tree Str Inc., Ashland, OR).
Immunofluorescence microscopy of platelet TLR4
Gel-filtered platelets (1 × 108/mL) were either unstimu-
lated or activated with 0.1 unit/ml thrombin or 10 μM
ADP. Following activation, platelets were fixed in 1%
paraformaldehyde for 15 min at room temperature and
concentrated onto microscope slides using a cytocentri-
fuge (Cytospin 4, ThermoScientific Inc., Grand Island,
NY) at 1500 rpm for 5 min. Platelets were then washed 3
times in phosphate buffered saline (pH 7.4) and were ei-
ther unpermeabilized or permeabilized with 0.1% NP40
(Surfact-AMPs™ NP-40, Pierce, Rockford, IL) for 2 min
at room temperature. After washing, cells were blocked
with 10% bovine serum albumin (1 h, 37 °C), and subse-
quently incubated with biotinylated mouse anti-human
monoclonal antibody to TLR4 (25 μg/ml, Clone:
HTA125, BioRad Laboratories, Hercules, CA) (1 h,
37 °C), followed by streptavidin conjugated to Alexa
Fluor 555 (1:200 in 2% BSA, S21381, ThermoFisher Sci-
entific, Waltham, MA) (1 h, 37 °C). P-selectin (CD62P)
and integrin β3a (CD61) were detected by incubating
cells with rat anti-mouse CD62P monoclonal ab (10 μg/
ml, Clone:RB40.34, BD Biosciences, San Diego, CA) and
mouse anti-human monoclonal antibody (1 μg/ml,
Clone:VI-PL2, eBioscience), respectively, followed by in-
cubation with Alexa Fluor 488-conjugated goat anti-rat
IgG and Alexa Fluor 405-conjugated goat anti-mouse
IgG (eBioscience, ThermoFisher Scientific, Waltham,
MA) overnight at 4 °C. The final dilution of all the
secondary antibodies used was 1:50 diluted in 5% goat
serum. After washing, a #1.5 glass coverslip was placed
on the cells with an anti-fade mounting medium (Pro-
Long Gold, ThermoFisher Scientific, Waltham, MA) and
cured overnight at 4 °C. Interfrence controls were pre-
pared by excluding incubation with the primary anti-
bodies in the second immuno-labelling step.
Fluorescent images were acquired using a combination
of confocal and super-resolution stimulated emission de-
pletion (STED) microscopy (Leica TCS SP8 STED 3x,
Leica Microsystems, Buffalo Grove, IL). Imaging powers
of STED wavelengths were set to 20 to 50% of excitation
wavelengths. The following imaging sequence was
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performed to avoid photobleaching: 1. CD61 was first
detected by confocal microscopy excited with 405 nm
with 1–6 nsec HyD gating; 2. Alexa Fluor 555 (TLR4)
was then excited with 555 nm and 660 nm STED deple-
tion laser; 3. Alexa Fluor 488 (P-selectin) was excited
with 488 nm and 592 nm STED depletion laser with
1.2–6 nsec HyD gating. All images were acquired at
100x magnification with pixel dwell time of 800 nsec;
pixel size (20 to 25 nm) was optimized at four times the
image format of 512 × 512 pixels. Deconvolution of
microscope images was performed using commercially
available software (Huygens Professional, 18.10, Sceinti-
fic Folume Imaging) and analyzed using publically avail-
able software (FIJI, NIH).
Thromboxane B2 ELISA
Resting or ADP-primed platelets (10 μM ADP,15min,
37 °C) were treated with 5 μg/ml E.coli 0111:B4 LPS
(EMD Millipore, Temecula, CA) for 30min at 37 °C.
Platelets pre-treated with 100 μM acetylsalicytic acid
(ASA) (Sigma-Aldrich, St. Louis, MO) (30min, 37 °C)
served as negative control. Immediately following stimula-
tion, samples were centrifuged (1500 RPM, 18 °C, 10min,
no brakes) and platelet supernatant was collected, flash
frozen in liquid nitrogen and stored at − 80 °C until ana-
lysis. Concentration of thromboxane B2 (TxB2) in the
platelet supernatant was measured using a commercial
ELISA kit (Enzo Life Sciences Inc., Farmingdale, NY).
Platelet TLR4 inhibition
Gel-filtered platelets, corrected to 1 × 107 cells/ml with
Tyrodes-HEPES, were either incubated with preservative-
free function blocking antibody to TLR4 (50 μg/ml, Clone:
HTA125, BioRad Laboratories, Hercules, CA) or equiva-
lent concentration of mouse IgG2a (Clone: OX-34Mouse
IgG2a, BioRad Laboratories, Hercules, CA) as isotype
control for 20min at room temperature. An additional
population of platelets were incubated with 50 μg/ml ul-
trapure LPS from Rhodobacter sphaeroides (LPS-RS)
(InvivoGen, San Diego, CA), a TLR4 antagonist, for 1 h at
37 °C. Following TLR4 blocking, platelets were either un-
stimulated (resting) or stimulated with 10 μM ADP (15
min, 37 °C) before treatment with 5 μg/ml LPS (30min,
37 °C). CD62P and CD61 were labeled as described above
in room temperature.
Inhibition of platelet cyclooxygenase-1
Platelets (1 × 107 cells/ml) were first treated with 100 μM
ASA or an equal volume of deionized water as vehicle
control, for 30 min at 37 °C. Resting or ADP-stimulated
(10 μM, 15min) platelets were then treated with 5 μg/ml
LPS for 30 min at 37 °C. Surface P-selectin and CD61
were labeled and detected by flow cytometry as de-
scribed above.
Statistical analysis
Normality of data was tested using Shapiro-Wilk nor-
mality test or visual inspection of normal quartile plots.
Non-parametric data were presented as median and
interquartile range (IQR) and parametric data were pre-
sented as mean ± standard deviation. Normally distrib-
uted and paired data were analyzed using t-tests while
nonparametric and paired data were analyzed using
Wilcoxon signed-rank test. Unpaired data was measured
using either Mann-Whitney U test or unpaired t test.
One-way repeated measures ANOVA was used for com-
paring the means of dose-response studies followed by
post-hoc analysis using Dunnet test. Data that violated
the assumption of sphericity were analyzed using
Greenhouse-Geisser correction. Correlation and correl-
ation coefficiency were calculated using Pearson correl-
ation. An alpha-priori of < 0.05 was considered
statistically significant. Interindividual variability was cal-
culated as the ratio between the standard deviation of a
group and its means and expressed as coefficient of vari-
ation (CV). Data were analyzed using commercially
available software (Prism 7.0,GraphPad Software, La
Jolla, CA).
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